Bill Meagher's focus with The Deal is on small and microcap equity finance, healthcare and biotechnology, PIPEs, and companies going public. His work has appeared in newspapers and magazines throughout California as well as on PBS, “60 Minutes,” ABC News and CNBC. Meagher has also written video scripts and produced national events for a non-profit educational organization and ghost written two books.
Recent Articles By The Author
Purdue Pharma Unloads Sales Staff, Transitioning From Painkiller Focus
After Purdue let some of its sales staff go in February, it followed up June 20 by sending the rest of the staff packing.
Sarepta Shares Skyrocket on Early Results for DMD Gene Therapy
The Duchenne Muscular Dystrophy specialist announces early results that show a gene-based treatment for the debilitating disease may be just two years away.
Creates Act Clears Committee Vote, Could Ease Way for Generic Drugmakers
While the CREATES ACT passed out of committee in the Senate, Senator Orrin Hatch, who helped pave the way for generic drugs in the U.S,,voted against the measure.
Azar Defends Trump Drug Pricing Plan, Faces Doubts From Senate
The health and human services secretary calls for getting rid of rebates between pharmacy benefit managers and drug companies, but senators had plenty of other issues with the Trump administration's blueprint to lower drug prices.
Senate Panel Considers Bill Aimed at Getting Generic Drugs to Market Faster
A healthcare bill supported on both sides of the aisle was held up until Sen. Chuck Grassley talked with pharma companies.
Cannabis Company Green Thumb Industries Heads to Canada to Go Public
Chicago-based Green Thumb Industries is the latest cannabis company to abandon hope of a U.S. IPO in favor of a reverse takeover in Canada and access to growth capital.
Sanofi, Merck and J&J Tout Lower Drug Prices
While a handful of drug companies say their average net prices have dropped, FDA Commissioner Scott Gottlieb announces a plan to encourage drug competition in the face of monopolies.
With 'Right to Try' Now Law, FDA Must Find a Way to Make It Work
The Right to Try Act has been championed as a way to give seriously ill patients more options, but the author of bill says it is about getting FDA out of 'people's lives.'
FDA Moves to Make Life Easier for Generic Drug Companies
Following up on a pledge to accelerate generic drugs into the marketplace to stoke price competition, the agency signals pending reform of the Risk Evaluation and Mitigation Strategy.
Drug Companies Likely Have Little to Fear From Trump's Policies -- So Far
The Congressional Budget Office scoring is out and stock analysts think drug companies are sitting pretty.